Product Description
lower price 98.5% ~100.5% Almost white crystalline powder Cefepime hydrochloride 123171-59-5
AI Product Description
*The following content is generated by AI and is for reference only.
Cefepime hydrochloride is a fourth-generation cephalosporin antibiotic widely utilized in clinical settings for the treatment of severe bacterial infections. Characterized as an almost white crystalline powder with a purity range typically between 98.5% and 100.5%, this pharmaceutical intermediate meets rigorous international quality standards. Its molecular formula is C₁₉H₂₄N₆O₅S₂·HCl, reflecting its complex chemical structure which includes a dihydrothiazine ring fused to a beta-lactam core, essential for its broad-spectrum antimicrobial activity. The unique quaternary ammonium group in its side chain significantly enhances its ability to penetrate the outer membrane of Gram-negative bacteria while maintaining stability against many beta-lactamases produced by resistant strains.
The CAS number for Cefepime hydrochloride is 103114-27-2, a critical identifier used globally for regulatory compliance, inventory management, and safety data sheet documentation. This compound is primarily indicated for managing complicated intra-abdominal infections, skin and skin structure infections, pneumonia, urinary tract infections, and septicemia caused by susceptible organisms such as *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*. Its pharmacological profile allows for once or twice-daily dosing, offering convenience in hospital and outpatient care environments.
In the manufacturing sector, high-purity Cefepime hydrochloride serves as the active pharmaceutical ingredient (API) for various injectable formulations, including vials and infusion bags. The "lower price" aspect mentioned in product descriptions often refers to competitive market rates achieved through optimized synthesis processes or bulk procurement, making it an attractive option for generic drug manufacturers seeking cost-effective solutions without compromising efficacy. As resistance patterns evolve, the role of fourth-generation cephalosporins remains vital in preserving patient outcomes against multidrug-resistant pathogens. Strict adherence to Good Manufacturing Practices (GMP) ensures that batches labeled with 98.5% to 100.5% purity deliver consistent therapeutic results, supporting global efforts to combat infectious diseases effectively.